Immune Checkpoint Inhibition in Lung Cancer Toxicity Management

Immune checkpoint inhibitors have transformed the treatment landscape of advanced non-small cell lung cancer by unleashing antitumour T-cell responses through blockade of regulatory receptors. Despite durable responses in many patients, these agents carry the risk of immune-related adverse events affecting multiple organs, with the lung being especially vulnerable. Management of pulmonary toxicity involves early recognition of checkpoint inhibitor pneumonitis, stratification of severity and prompt intervention with immunosuppressive therapy or treatment interruption. Identification of clinical and biological risk factors, coupled with refined diagnostic criteria and imaging patterns, is critical to balancing efficacy and safety. Emerging evidence emphasises the need for multidisciplinary protocols, incorporation of predictive biomarkers and personalised tapering schedules to mitigate severe lung injury without compromising antitumour benefit.

Research from Nature Portfolio

Meta-analytic findings have established that agents targeting the programmed cell death protein 1 axis carry a significantly elevated risk of pneumonitis compared with conventional chemotherapy, with non-small cell lung cancer patients bearing one of the highest incidences. Dose intensity appears not to influence pneumonitis frequency, underscoring an on-target immune mechanism. In a large real-world cohort, performance status of two or above and a heavy smoking history emerged as independent predictors of clinically significant interstitial lung disease following checkpoint inhibition. These insights have informed risk stratification tools that may guide treatment selection and surveillance strategies in lung cancer populations receiving immunotherapy.

Immune Checkpoint Inhibition in Lung Cancer Toxicity Management publication trend

The graph below shows the total number of articles in immune checkpoint inhibition in lung cancer toxicity management across all publications each year (not limited to Nature Index journals).

Technical terms

Immune checkpoint inhibitor (ICI): A therapeutic antibody that blocks inhibitory receptors on T cells to enhance antitumour immunity.

Immune-related adverse event (irAE): Toxicity resulting from off-target immune activation induced by checkpoint blockade.

Checkpoint inhibitor pneumonitis (CIP): Inflammatory lung injury characterised by ground-glass opacities and interstitial infiltrates following ICI therapy.

Interstitial lung disease (ILD): A group of diffuse parenchymal disorders marked by fibrosis and inflammation of the lung interstitium.

Programmed cell death protein 1 (PD-1) and ligand 1 (PD-L1): A receptor–ligand pair that negatively regulates T-cell activity; blockade restores immune function.

References

1. PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. Scientific Reports (2017).
2. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study. Scientific Reports (2020).
3. Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management. Frontiers in Immunology (2021).
4. Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism. Frontiers in Immunology (2022).
5. Pulmonary toxicity of immune checkpoint immunotherapy. Journal of Clinical Investigation (2024).